Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot for eczema shows promise in Mid-Stage trial

NCT ID NCT06718101

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard treatments. About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. The goal is to see if it reduces skin rash and itching safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lutikizumab (ABT-981), a drug given as a shot under the skin
What this could lead to
If it works, this could point toward a new treatment option for people with moderate to severe eczema that hasn't responded to standard creams or pills.
What could go wrong
This is an early Phase 2 trial with only 83 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

83 people

The number who actually took part.

Started

Dec 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of AD with onset of symptoms at least 1 year prior to the Baseline Visit and participant meets Hanifin and Rajka criteria. * Participant has applied non-medicated, additive-free bland emollient twice daily for at least 7 days before the Baseline Visit. * History of inadequate response to topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), or topical JAK inhibitors, OR systemic treatment for AD, OR participants for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks). Exclusion Criteria: * Use of the following AD treatments within the specified washout period prior to the Baseline Visit: \-- Systemic therapy for AD, including but not limited to corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE4) inhibitors, IFN-γ, and mycophenolate mofetil within 5 half-lives \[if known\] or within 4 weeks, whichever is longer; \-- Any biologic treatments, (within 5 half-lives \[if known\]) or within 12 weeks (whichever is longer), or as specified below: \< 8 weeks for dupilumab; \< 12 weeks for nemolizumab; \< 16 weeks for tralokinumab and lebrikizumab. * Phototherapy treatment, laser therapy, tanning booth, or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks. * Herbal treatments (e.g., traditional Chinese medicines) within 4 weeks. * Topical treatments (with the exception of non-medicated, additive-free bland emollients), including but not limited to TCS, TCIs, or topical PDE-4 inhibitors within 7 days. * Topical JAK inhibitor within 14 days. * Systemic JAK inhibitor (including but not limited to ruxolitinib, tofacitinib, baricitinib, upadacitinib, abrocitinib \[PF-04965842\], and filgotinib) within 5 half-lives \[if known\] or within 14 days, whichever is longer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Advanced Clinical Research Institute - Tampa /ID# 272558

    Tampa, Florida, 33607, United States

  • Arlington Dermatology /ID# 271735

    Rolling Meadows, Illinois, 60008, United States

  • Center for Clinical Studies - Clear Lake /ID# 271749

    Webster, Texas, 77598, United States

  • Chapel Allerton Hospital /ID# 274762

    Leeds, West Yorkshire, LS7 4SA, United Kingdom

  • Clinical Partners /ID# 271791

    Johnston, Rhode Island, 02919, United States

  • Clinical Trials Research Institute /ID# 274234

    Thousand Oaks, California, 91320, United States

  • Complete Dermatology - Sugar Land /ID# 274240

    Sugar Land, Texas, 77479, United States

  • Dermatology Associates of Tyler /ID# 273684

    Tyler, Texas, 75703, United States

  • Dermatology Research Associates - Los Angeles /ID# 272945

    Los Angeles, California, 90045, United States

  • Encore Medical Research - Weston /ID# 272539

    Weston, Florida, 33331, United States

  • Equity Medical /ID# 272555

    New York, New York, 10023-7340, United States

  • Hallym University Kangnam Sacred Heart Hospital /ID# 271785

    Seoul, Seoul Teugbyeolsi, 07441, South Korea

  • Health Concepts /ID# 271744

    Rapid City, South Dakota, 57702, United States

  • Integrative Skin Science and Research /ID# 274243

    Sacramento, California, 95815, United States

  • Konkuk University Medical Center /ID# 271789

    Seoul, Seoul Teugbyeolsi, 05030, South Korea

  • Korea University Ansan Hospital /ID# 271786

    Ansan-si, Gyeonggido, 15355, South Korea

  • Kyoto University Hospital /ID# 275237

    Kyoto, Kyoto, 606-8507, Japan

  • Medical Corporation Kojinkai Sapporo Dermatology Clinic /ID# 273619

    Sapporo, Hokkaido, 060-0063, Japan

  • Oregon Dermatology and Research Center /ID# 271733

    Portland, Oregon, 97210, United States

  • Orion Clinical Research /ID# 274236

    Austin, Texas, 78759, United States

  • Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550

    Fountain Hills, Arizona, 85268, United States

  • Research Associates of South Florida /ID# 272549

    Miami, Florida, 33134, United States

  • Royal Liverpool University Hospital /ID# 272584

    Liverpool, L7 8XP, United Kingdom

  • Royal United Hospital /ID# 274328

    Bath, Bath And North East Somerset, BA1 3NG, United Kingdom

  • Seoul National University Hospital /ID# 271787

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Skin Care Research Boca Raton /ID# 272544

    Boca Raton, Florida, 33486-2269, United States

  • Somnos Clinical Research /ID# 272943

    Lincoln, Nebraska, 68510, United States

  • Soon Chun Hyang University Hospital Bucheon /ID# 271788

    Bucheon-si, Gyeonggido, 14584, South Korea

  • Tachikawa Dermatology Clinic /ID# 273620

    Tachikawa-shi, Tokyo, 190-0023, Japan

  • Western States Clinical Res /ID# 271748

    Wheat Ridge, Colorado, 80033-2896, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.